

DESCRIPTION

Source	Chinese Hamster Ovary cell line, CHO-derived mouse Integrin alpha 7 beta 1 protein				
	Mouse Integrin $\alpha 7$ (Phe34-Glu1033) Accession # NP_032424	His-Pro	GGGSGGGS	Acidic Tail	6-His tag
	Mouse Integrin $\beta 1$ (Gln21-Asp728) Accession # P09055	His-Pro	GGGSGGGS	Basic Tail	
	N-terminus				C-terminus
N-terminal Sequence Analysis	Phe34, Glu915 (Integrin $\alpha 7$) & Gln21 predicted, No results obtained: sequencing might be blocked (Integrin $\beta 1$)				
Structure / Form	Noncovalently-linked heterodimer				
Predicted Molecular Mass	119 kDa (Integrin $\alpha 7$, full length), 22.4 kDa (Integrin $\alpha 7$, N-terminus starts at Glu915) & 86.5 kDa (Integrin $\beta 1$)				

SPECIFICATIONS

SDS-PAGE	123-157 kDa, 95-100 kDa & 38-42 kDa, reducing conditions
Activity	Measured by its binding ability in a functional ELISA. When mouse Laminin I (Catalog # 3400-010-02) is coated at 10 $\mu\text{g}/\text{mL}$, Recombinant Mouse Integrin $\alpha 7\beta 1$ binds with an apparent $K_D < 0.5 \text{ nM}$.
Endotoxin Level	<0.01 EU per 1 μg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 400 $\mu\text{g}/\text{mL}$ in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	<p>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</p> <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 $^{\circ}\text{C}$ as supplied. • 1 month, 2 to 8 $^{\circ}\text{C}$ under sterile conditions after reconstitution. • 3 months, -20 to -70 $^{\circ}\text{C}$ under sterile conditions after reconstitution.

BACKGROUND

Integrin $\alpha 7\beta 1$, also called VLA-7 (very late antigen-7), is the major laminin-binding integrin in cardiac and skeletal muscle (1-4). The non-covalent heterodimer is composed of ~150 kDa $\alpha 7$ and 130 kDa $\beta 1/\text{CD}29$ type I transmembrane glycoprotein subunits with short cytoplasmic tails (2). While $\alpha 7$ pairs only with $\beta 1$, twelve integrins share the $\beta 1$ subunit (1-5). The longest version of $\alpha 7$ is the X1X2B form, encoding 1179 amino acids (aa). Six alternatively spliced 1116-1160 aa isoforms of the $\alpha 7$ subunits have short extracellular (X1, X2) or cytoplasmic (A, C) deletions. Isoforms are differentially expressed by tissue and developmental stage and may show preferences for specific laminins (3-5). The $\beta 1$ vWFA domain participates with the $\alpha 7$ FG-GAP motifs in ligand binding. The $\alpha 7$ subunit is cleaved into extracellular heavy and transmembrane/cytoplasmic light chains (3). The mouse $\alpha 7$ heavy chain shares 89%, 90%, 87% and 85% aa sequence identity with human, rat, feline and bovine $\alpha 7$, and the mouse $\beta 1$ ECD shares 98% aa identity with rat and 93-94% with human, bovine, porcine, ovine, canine and feline $\beta 1$. The $\alpha 7$ heavy chain in species other than mouse may also be cleaved at aa 603-605 by a serine protease; fragments remain associated. This form enhances the active, unfolded and open conformation, promoting cell adhesion and spreading (1, 2, 6). Adhesion of $\alpha 7\beta 1$ to laminin-111 accounts for many of its effects, but $\alpha 7\beta 1$ also binds most other laminins (5). It protects muscle from exercise-induced damage, and its absence in humans or mice causes a form of muscular dystrophy (7-9). $\alpha 7\beta 1$ is also expressed in vascular smooth muscle (VSM), and is important for development of the cerebral vasculature (10). VSM cells show increased $\alpha 7\beta 1$ expression and enhanced laminin binding in injury-induced atherosclerosis or PDGF treatment (11, 12). Deletion of $\alpha 7$ results in VSM hyperplasia, especially in response to injury (13).

References:

1. Takada, Y. *et al.* (2007) *Genome Biol.* **8**:215.
2. Luo, B-H. *et al.* (2007) *Annu. Rev. Immunol.* **25**:619.
3. Ziober, B.L. *et al.* (1993) *J. Biol. Chem.* **268**:26773.
4. Song, W.K. *et al.* (1993) *J. Cell Sci.* **106**:1139.
5. Nishiuchi, R. *et al.* (2006) *Matrix Biol.* **25**:189.
6. Liu, J. *et al.* (2008) *J. Biol. Chem.* **283**:35668.
7. Mayer, U. *et al.* (1997) *Nat. Genet.* **17**:318.
8. Boppart, M.D. *et al.* (2006) *Am. J. Physiol. Cell. Physiol.* **290**:C1660.
9. Hodges, B.L. *et al.* (1997) *J. Cell Sci.* **110**:2873.
10. Flintoff-Dye, N.L. *et al.* (2005) *Dev. Dyn.* **234**:11.
11. Chao, J.T. *et al.* (2006) *Am. J. Physiol. Cell. Physiol.* **290**:C972.
12. Chao, J.T. *et al.* (2004) *Am. J. Physiol. Heart Circ. Physiol.* **287**:H381.
13. Welser, J.V. *et al.* (2007) *Circ. Res.* **101**:672.